Abstract
Introduction. The risk of metabolic syndrome in patients with schizophrenia is significantly higher than in the general population. The consequence of this fact is the shortening of life in this group of patients by as much as 20–25%. The search for methods leading to the reduction of metabolic syndrome risk factors is essential in preventing cardiovascular consequences. Dysbiosis disrupts the integrity of the intestinal barrier, contributing to general inflammation. This process is associated with metabolic disorders, sugar metabolism and obesity.
A case report. A description of a 24-year-old patient suffering from paranoid schizophrenia is presented. Due to the lack of mental state improvement and periods of lack of cooperation, pharmacotherapy was modified many times. Finally, remission was achieved after the use of clozapine with paroxetine. The patient was diagnosed with metabolic syndrome. A probiotic sealing the blood-intestines barrier was added to the treatment. After 3 months of using the probiotic, normalisation of the level of glycemia, total cholesterol, LDL, lowering of the level of insulin, and reduction in the level of insulin resistance were observed.
Conclusions. The introduction of a probiotic with properties sealing the blood-intestines barrier to the treatment may result in a reduction in the risk parameters of the metabolic syndrome. It is advisable to conduct further research to confirm the above observations.